ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Profitability
This table compares ANI Pharmaceuticals and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 4.91% | 26.73% | 8.86% |
| Aligos Therapeutics | -3,267.65% | -39.35% | -22.09% |
Valuation and Earnings
This table compares ANI Pharmaceuticals and Aligos Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $614.38 million | 2.99 | -$18.52 million | $1.63 | 50.17 |
| Aligos Therapeutics | $3.94 million | 15.59 | -$131.21 million | ($19.76) | -0.51 |
ANI Pharmaceuticals has higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ANI Pharmaceuticals has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for ANI Pharmaceuticals and Aligos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 1 | 7 | 2 | 3.10 |
| Aligos Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
ANI Pharmaceuticals presently has a consensus target price of $99.29, suggesting a potential upside of 21.42%. Aligos Therapeutics has a consensus target price of $50.00, suggesting a potential upside of 400.50%. Given Aligos Therapeutics’ higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than ANI Pharmaceuticals.
Institutional and Insider Ownership
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
ANI Pharmaceuticals beats Aligos Therapeutics on 12 of the 15 factors compared between the two stocks.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
